Phase II clinical trials with rhizoxin in breast cancer and melanoma
- 1 February 1996
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 73 (3), 397-399
- https://doi.org/10.1038/bjc.1996.68
Abstract
Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determine the clinical activity of this compound in patients with advanced breast cancer and melanoma. Based on the results of a phase I study, 2.0 mg m-2 was administered as intravenous infusion over 5 min every 21 days. Nineteen patients were entered into the breast cancer phase II trial and received a total of 50 courses (median 2, range 1-6). Of these, dose reductions were performed in three courses because of leucopenia or stomatitis (1.5 mg m-2, one course; 1.45 mg m-2, two courses). Twenty-six patients were entered into the melanoma trial and received a total of 70 courses (median 2, range 1-12). No dose reductions were required. All patients were eligible for toxicity. Haematological toxicity included neutropenia CTC grade 3 (29/120 courses, 24.2%) and grade 4 (11/20 courses, 9.2%). Only drug-related CTC grade 1 thrombocytopenia was observed. Non-haematological toxicity included alopecia in all patients after two courses of treatment as well as CTC grade 3/4 stomatitis and asthenia. In the breast cancer study, one patient achieved a more than 50% tumour reduction after six cycles but was progressing after 6 weeks. Another patient showed a partial remission after the first course but was taken off the study because of CTC grade 3 skin toxicity. One patient was not evaluable for response (early death). No objective remissions were observed in 15 evaluable patients. In melanoma, no objective remissions were observed. We conclude that rhizoxin can be safely administered at 2.0 mg m-2 every 3 weeks. However, it has little activity in patients with advanced breast cancer and melanoma.Keywords
This publication has 15 references indexed in Scilit:
- Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancerBritish Journal of Cancer, 1995
- Prelinical and Phase I Studies With Rhizoxin to Apply a Pharmacokinetically Guided Dose-Escalation SchemeJNCI Journal of the National Cancer Institute, 1992
- Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.Journal of Biological Chemistry, 1990
- Rhizoxin resistant mutants with an altered β-tubulin gene in Aspergillus nidulansMolecular Genetics and Genomics, 1989
- [The structure and antitumor activity of antitumor antibiotics--recent progress].1988
- Rhizoxin binding to tubulin at the maytansine-binding siteBiochimica et Biophysica Acta (BBA) - General Subjects, 1987
- Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.The Journal of Antibiotics, 1987
- A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F.The Journal of Antibiotics, 1986
- Studies on macrocyclic lactone antibiotics. VIII. Absolute structures of rhizoxin and a related compound.The Journal of Antibiotics, 1986
- Studies on macrocyclic lactone antibiotics. VII Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis.The Journal of Antibiotics, 1984